Interaction Checker
Potential Weak Interaction
Raltegravir (RAL)
Rilpivirine/ Emtricitabine/Tenofovir-DF (RPV/FTC/TDF)
Quality of Evidence: Very Low
Summary:
Eviplera/Complera (rilpivirine, emtricitabine, tenofovir-DF) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with raltegravir would be possible from a pharmacokinetic standpoint as no clinically relevant drug-drug interaction is expected between raltegravir and rilpivirine, emtricitabine or tenofovir-DF. Coadministration of raltegravir and rilpivirine increased raltegravir AUC, Cmin and Cmax by 9%, 27% and 10%, respectively, with no change in rilpivirine AUC, Cmin or Cmax. Population PK analysis showed emtricitabine/tenofovir-DF had minimal effect on the pharmacokinetics of once daily raltegravir (12% increase in relative bioavailability). Coadministration of tenofovir-DF and raltegravir (400 mg twice daily) increased raltegravir AUC (49%) and Cmax (64%), but had no effect on Cmin; tenofovir AUC, Cmax and Cmin decreased by 10%, 23% and 13%, respectively. The safety profile observed in patients who used atazanavir and/or tenofovir-DF (both agents that increase raltegravir concentrations) was generally similar to that of patients who did not use these agents. No clinically significant interaction is expected with emtricitabine. No dose adjustment is required when coadministered with twice daily or once daily raltegravir.
Description:
View all available interactions with Raltegravir (RAL) by clicking here.
No Version Present
Copyright © 2024 The University of Liverpool. All rights reserved.